Tandem Diabetes Care (TNDM) Set to Announce Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Tandem Diabetes Care has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The company had revenue of $221.90 million for the quarter, compared to analyst estimates of $205.63 million. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $32.93 on Wednesday. Tandem Diabetes Care has a one year low of $13.82 and a one year high of $53.69. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -15.47 and a beta of 1.33. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05. The firm has a 50-day simple moving average of $40.75 and a two-hundred day simple moving average of $41.91.

Wall Street Analysts Forecast Growth

TNDM has been the subject of several recent analyst reports. Canaccord Genuity Group initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 target price for the company. The Goldman Sachs Group began coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 target price on the stock. Robert W. Baird increased their price target on Tandem Diabetes Care from $36.00 to $39.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Morgan Stanley restated an “equal weight” rating and set a $45.00 price target on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Finally, Royal Bank of Canada assumed coverage on shares of Tandem Diabetes Care in a research report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price objective for the company. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $55.13.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.